,28 The combination of anti-PD1 immunotherapy with PARP inhibitor has been explored in NSCLC with suggested synergy29,30 The rationale for combining a PARP inhibitor and PD1 or PDL1 immune checkpoint inhibitor has led to the development of the ORION randomised phase II trial (NCT03775486), which is evaluating checkpoint inhibition with the anti-PDL1 antibody durvalumab with or without olaparib as maintenance therapy in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.